NCT06653010暂停早期 1 期
A Clinical Study on the Safety and Efficacy of Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer
Wondercel Biotech (ShenZhen)2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年10月23日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 暂停
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Maximum Tolerated Dose (MTD)
研究概览
简要总结
This is an investigator initiated trial to assess the efficacy and safety of a GCC-targeting CAR-T therapy (REVO-UWD-01) in the metastatic colorectal cancer. It also aims to explore the feasibility of using a novel universal CAR-T cell platform.
详细描述
The study will use T cells from healthy donors, modified using a novel universal CAR-T technology, to treat metastatic colorectal cancer patients. The antigen-binding site of the CAR molecule recognizes GCC as the target.
The main questions it aims to answer are:
- What is the maximum tolerated dose (MTD) of GCC-CAR-T therapy in universal CAR-T cell treatments?
- What are the dose-limiting toxicities (DLT) and treatment-emergent adverse events (TEAE)?
- What is the treatment's efficacy, as measured by objective response rate (ORR) and progression-free survival (PFS)? Researchers will assess whether universal CAR-T cells have good safety and efficacy in treating colorectal cancer, while improving accessibility and lowering treatment costs.
Participants will:
- Receive universal GCC-CAR-T cells through a 3+3 dose escalation scheme.
- Undergo chemotherapy conditioning before CAR-T infusion.
- Be monitored for adverse events, immune response, and disease progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: ≥18 years and ≤75 years old.
- •Pathological Diagnosis: Pathologically confirmed metastatic colorectal cancer with radiographically confirmed metastatic lesions (e.g., CT or MRI).
- •GCC Expression: Tumor lesions assessed by immunohistochemistry (IHC) showing GCC expression ≥1+ in ≥50% of the area (randomly select at least 5 fields from tumor regions for evaluation; at least 5 unstained slides must be provided for assessment).
- •Measurable Lesions: At least one measurable lesion per RECIST 1.1 criteria; measurable lesions should not have received prior radiotherapy or interventional local therapy (lesions in previously irradiated or locally treated fields may be selected as target lesions if confirmed to have progressed).
- •Prior Treatment: Participants with advanced colorectal cancer who have progressed or are intolerant after ≥2 lines of standard therapy (with clear documentation).
- •ECOG Performance Status: 0 or
- •Expected Survival: ≥90 days (as assessed by the investigator based on the participant's clinical condition).
- •Organ Function:
- •Absolute neutrophil count ≥1.5 × 10⁹/L;
- •Platelet count ≥80 × 10⁹/L;
- •Hemoglobin ≥9 g/dL;
- •Liver function:
- •Total bilirubin ≤1.5 × ULN (≤2.0 × ULN for Gilbert's syndrome);
- •AST and ALT ≤5 × ULN;
- •INR <1.3 (INR <3 for participants on anticoagulant therapy);
- •Serum creatinine ≤1.5 mg/dL (132.6 μmol/L) or eGFR ≥50 mL/min/1.73 m²;
- •Cardiac ejection fraction >50%.
- •Bleeding Risk: No active bleeding or bleeding tendency.
- •Fertility Requirements:
- •Women of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment and agree to use effective contraception during treatment and for 8 weeks after the last dose;
- •Male participants must also use effective contraception during treatment and for 8 weeks after the last dose.
- •Informed Consent: Participants voluntarily enroll in the study, provide signed informed consent, demonstrate good compliance, and cooperate with follow-up.
排除标准
- •Pregnant or breastfeeding women;
- •Received chemotherapy, targeted therapy, monoclonal antibody therapy, or traditional Chinese medicine anti-tumor therapy within 14 days prior to cell collection;
- •Participated in another drug clinical trial within 4 weeks prior to study initiation;
- •Any of the following cardiovascular or cerebrovascular diseases or risk factors:
- •LVEF <50%;
- •NYHA Class III or IV heart failure;
- •History of myocarditis, cardiomyopathy, or myocardial infarction within 6 months prior to enrollment (unless cardiac function has recovered as confirmed by the investigator);
- •Uncontrolled arrhythmias (e.g., atrial fibrillation, ventricular tachycardia) or requiring long-term anti-arrhythmic therapy;
- •QTcF >480 ms on screening ECG;
- •Uncontrolled hypertension (systolic BP >160 mmHg or diastolic BP >100 mmHg);
- •History of ischemic or hemorrhagic stroke (unless stable for >6 months with no sequelae);
- •Uncontrolled intracranial lesions (e.g., brain tumors, aneurysms);
- •History of DVT or PE (unless on stable anticoagulant therapy for ≥6 months);
- •Significantly elevated troponin or BNP/NT-proBNP levels suggestive of potential cardiac injury or dysfunction;
- •Non-healing wounds or fractures for a prolonged period;
- •Coagulation disorders or bleeding diathesis;
- •History of substance abuse (including psychiatric drugs) that cannot be discontinued or history of psychiatric disorders;
- •Uncontrolled or active fungal, bacterial, viral, or other infections.
- •Prior anti-tumor treatment-related toxicities not recovered to ≤Grade 1 or to levels specified in the inclusion/exclusion criteria;
- •Known HIV infection; known active syphilis; or active hepatitis B (HBsAg-positive and HBV-DNA ≥500 IU/mL or above the lower limit of detection, whichever is higher) or hepatitis C (anti-HCV-positive and HCV-RNA above the lower limit of detection);
- •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage despite appropriate intervention;
- •Severe allergic reaction history to key study treatments (including fludarabine, cyclophosphamide, mycophenolate sodium, tocilizumab, and anti-infective agents used during preconditioning);
- •Active autoimmune disease requiring systemic treatment within 2 years (including but not limited to autoimmune hepatitis, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism); physiologic corticosteroid replacement therapy (e.g., thyroxine, insulin, or corticosteroids for adrenal or pituitary insufficiency) is not considered systemic treatment;
- •Female participants unwilling to use contraception from informed consent through 6 months after CAR-T cell infusion;
- •Participants with leptomeningeal metastasis, brainstem metastasis, spinal cord metastasis and/or compression, or active/symptomatic CNS metastases not treated locally;
- •History of interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroid treatment;
- •Clinically significant pulmonary impairment due to lung comorbidities, including but not limited to underlying pulmonary disease (e.g., pulmonary embolism, severe asthma, or severe COPD within 3 months prior to enrollment), any autoimmune, connective tissue, or inflammatory disorders involving the lungs (e.g., rheumatoid arthritis, sarcoidosis), or prior pneumonectomy;
- •Any condition deemed by the investigator to interfere with drug evaluation, participant safety, or study outcomes, or any other condition making the participant unsuitable for the study.
研究组 & 干预措施
Single dose injection of REVO-UWD-01
Experimental
Dose escalation will be performed for the single dose injection of REVO-UWD-01 for treating mCRC
干预措施: Universal CAR-T cells injection for treating mCRC (Biological)
结局指标
主要结局
Maximum Tolerated Dose (MTD)
时间窗: Within the first month post-infusion.
The highest dose of GCC-CAR-T cells that can be administered without causing unacceptable side effects, measured during the dose escalation phase.
Dose-Limiting Toxicities (DLT)
时间窗: Within the first month post-infusion.
The incidence of treatment-related toxicities that prevent further dose escalation.
Treatment-Emergent Adverse Events (TEAE)
时间窗: From the administration of UWD-01 CAR-T cells through six months post-infusion
The frequency and severity of adverse events that arise following the administration of UWD-01-CAR-T cells.
次要结局
- Objective Response Rate (ORR)(Measured at 3 and 6 months after treatment.)
- Progression-Free Survival (PFS)(From the start of treatment up to 5 years.)
- Overall Survival (OS)(From the start of treatment up to maximum follow-up period of five years.)
- Duration of Response (DOR)(From the administration of UWD-01 CAR-T cells to a maximum follow-up period of five years.)
研究者
研究点 (2)
Loading locations...
相似试验
暂停
1 期
Autologous CAR-T Cells (WD-01) for Metastatic Colorectal CancerNCT06675513Wondercel Biotech (ShenZhen)30
暂停
早期 1 期
Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung CancerNCT06653023Wondercel Biotech (ShenZhen)60
已完成
早期 1 期
CART Therapy in GUCY2C-positive Digestive Tract TumorsMalignant Neoplasms of Digestive OrgansNCT04652219Weijia Fang, MD1
招募中
1 期
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid TumorsPancreas CancerGastric CancerColon CancerEsophagus CancerLung CancerBreast CancerCholangiocarcinomaNCT06010862Chongqing Precision Biotech Co., Ltd36
终止
1 期
GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT05352542jianming xu10